News Catalyst to re-submit rare disease drug after trial success Already approved in EU, Catalyst aiming for FDA filing next year.
Views & Analysis Out of the darkness: new gene therapies for eye diseases US FDA expert committee’s ‘yes’ could pave the way for a new generation of gene therapies for rare inherited eye disorders.
Views & Analysis Shedding light on LHON: the rare blindness affecting young a... LHON is a frequently misdiagnosed condition that needs faster diagnosis.
Views & Analysis Orphan drugs: overcoming barriers to market access What manufacturers should consider, after successfully overcoming any HTA hurdles, to achieve market access.
Partner Content Partner Content Orphan medicines, advances, access and affordability LONDON, UNITED KINGDOM, April 19th 2017:
Views & Analysis Rethinking rare diseases: treat the whole patient CRDN wants to break down barriers in communication between rare disease patients, HCPs and industry.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
